| Filed On | Filing |
|---|---|
| 26 Oct 2026 |
8-K: Regulation FD Disclosure; Other Events
©2026 Oruka Therapeutics ©2026 ORUKA THERAPEUTICS EVERLAST - B Interim Data ORKA - 001 Phase 2b trial in psoriasis October 26, 2026 |
| 24 Aug 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On behalf of Oruka Therapeutics, Inc. (the “Company”), I am pleased to offer you the position of Chief Commercial Officer (the “Role”) pursuant to this letter agreement (the “Agreement”), provided you accept such offer as indicated by yo... |
| 10 Aug 2026 |
8-K: Results of Operations and Financial Condition
EVERLAST-A Week 28 data expected at the end of 3Q 2026; 52-week data for all participants expected in December 2026 |
| 04 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 2, 2026, Oruka Therapeutics, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). Set forth below is a brief description of each matter considered and voted upon at the Annual Meeting, together wit... |
| 01 Jun 2026 |
8-K: Other Events
This First Amendment to IL-23 License Agreement (this “First Amendment”) is dated as of May 29, 2026 (the “Amendment Effective Date”) and is entered into by and between Paragon Therapeutics, Inc., a corporation organized under the laws o... |
| 30 Apr 2026 |
8-K: Results of Operations and Financial Condition; Other Events
Oruka Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Leerink Partners LLC (“Leerink Partners”), TD Securities (USA) LLC, (“TD Securities”), Goldman Sachs & Co. LLC (“Goldman Sac... |
| 27 Apr 2026 |
8-K: Regulation FD Disclosure; Other Events
©2026 Oruka Therapeutics ©2026 ORUKA THERAPEUTICS EVERLAST - A Interim Data ORKA - 001 Phase 2a trial in psoriasis April 27, 2026 |
| 11 Dec 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
Re: Appointment to Oruka Therapeutics, Inc. Board of Directors |
| 22 Sep 2025 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of September 17, 2025, by and among Oruka Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreeme... |
| 01 Jul 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
On behalf of Oruka Therapeutics, Inc. (the “Company”), I am pleased to offer you the position of Chief Operating Officer (the “Role”) pursuant to this letter agreement (the “Agreement”). Your employment with the Company commenced on Marc... |
| 03 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On June 2, 2025, Oruka Therapeutics, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). Set forth below is a brief description of each matter considered and voted upon at the Annual Meeting, together wit... |
| 05 Feb 2025 |
8-K: Entry into a Material Definitive Agreement
IL-17A/F (ORKA-002) License Agreement – Paragon Therapeutics, Inc. |
| 19 Dec 2024 |
8-K: Entry into a Material Definitive Agreement
IL-23 (ORKA-001) License Agreement – Paragon Therapeutics, Inc. |
| 18 Nov 2024 |
8-K: Submission of Matters to a Vote of Security Holders
On November 14, 2024, Oruka Therapeutics, Inc. (the “Company”) held its Special Meeting of Stockholders (the “Special Meeting”). Set forth below is a brief description of each matter considered and voted upon at the Special Meeting, toge... |
| 14 Nov 2024 |
8-K: Other Events
To the Board of Directors and Stockholders of Oruka Therapeutics, Inc. |
| 04 Oct 2024 |
8-K: Departure/Election of Directors or Officers; Compensation
On behalf of the Board of Directors (the “Board”) of Oruka Therapeutics, Inc. (the “Company”), I am pleased to offer you a continuing position as Chief Executive Officer of the Company (“CEO”) and as a member of the Board pursuant to thi... |
| 13 Sep 2024 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +2 more
Certain identified information marked with [***] has been excluded from this exhibit because it is not material and is of the type that the registrant treats as private and confidential. |
| 05 Sep 2024 |
8-K: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +9 more
Defined terms included below shall have the same meaning as terms defined and included in the Company’s definitive proxy statement/prospectus filed with the U.S. Securities and Exchange Commission (the “SEC”) on July 22, 2024. |
| 27 Aug 2024 |
8-K: Other Events
ARCA biopharma Provides Update Regarding Special Dividend Amount in Connection with the Proposed Merger with Oruka Therapeutics |
| 23 Aug 2024 |
8-K: Submission of Matters to a Vote of Security Holders; Other Events
Westminster, CO, August 23, 2024 – ARCA biopharma, Inc. (NASDAQ: ABIO) (“ARCA”) today announced that its Board of Directors (the “Board”) has approved a reverse stock split of ARCA’s common stock at a ratio of 1-for-12. ARCA’s common sto... |
Loading...